Last reviewed · How we verify
Tenecteplase or Alteplase
Tenecteplase and alteplase are tissue plasminogen activators (tPA) that convert plasminogen to plasmin, which breaks down fibrin clots.
Tenecteplase and alteplase are tissue plasminogen activators (tPA) that convert plasminogen to plasmin, which breaks down fibrin clots. Used for Acute ischemic stroke, Acute myocardial infarction (ST-elevation MI), Pulmonary embolism.
At a glance
| Generic name | Tenecteplase or Alteplase |
|---|---|
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Drug class | Tissue plasminogen activator (tPA); fibrinolytic agent |
| Target | Plasminogen; fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Both drugs are serine proteases that bind to fibrin in blood clots and catalyze the conversion of plasminogen to plasmin, a potent fibrinolytic enzyme. Plasmin degrades the fibrin matrix that holds clots together, leading to clot dissolution. Tenecteplase is a genetically modified variant of alteplase with improved fibrin specificity and longer half-life, allowing for single-bolus dosing.
Approved indications
- Acute ischemic stroke
- Acute myocardial infarction (ST-elevation MI)
- Pulmonary embolism
Common side effects
- Bleeding (intracranial hemorrhage)
- Bleeding (major extracranial)
- Reperfusion arrhythmias
- Hypotension
- Allergic reactions
Key clinical trials
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice
- Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC (NA)
- Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions (PHASE3)
- Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial (PHASE2, PHASE3)
- Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis (PHASE3)
- Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenecteplase or Alteplase CI brief — competitive landscape report
- Tenecteplase or Alteplase updates RSS · CI watch RSS
- Insel Gruppe AG, University Hospital Bern portfolio CI